We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Climate change is happening and is due to human activities; along with warming, many other changes are occurring such as melting polar ice, rising sea levels and more frequent floods, droughts and heatwaves.
Guidance for vets and beekeepers on importing bee medicines when a product authorised in the UK is not suitable or available.
How marketing authorisation holders should inform MHRA of a signal or an ADR to a medicine.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Healthcare professionals should be vigilant for suspected adverse reactions and safety concerns associated with e-cigarettes and e-liquids, commonly known as vapes. Please report adverse reactions to the Yellow Card scheme and promote vigilance among patients.
How to use a cost effectiveness analysis to evaluate your digital health product.
Information about the risks of taking valproate medicines during pregnancy.
Apply for changes to your marketing authorisation, including minor variations type IA and IB, major variations type II and extensions.
Ultrasound has been used in medical practice throughout the world for at least 50 years.
Antipsychotic drugs available in the UK, their side effects and their effect on dementia patients.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 April 2024) approved the medicine fosdenopterin (Nulibry) to treat the genetic disease Molybdenum Cofactor Deficiency (MoCD) Type A
Information for public health professionals on immunisation.
Impact of parental conflict on local services, including education, health and social care, court systems, and drug and alcohol services.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.